ISCL/USCLC/EORTC response in viscera
| Response . | Lugano PET-CT–based response . | Lugano CT-based response . |
|---|---|---|
| CR | Complete metabolic response. Score of 1, 2, or 3* with or without a residual mass on 5PS. No evidence of FDG-avid disease. | No extralymphatic sites of disease. Any abnormal size of organ at screening/baseline has returned to normal size. BM normal by morphology. |
| PR | Partial metabolic response. Score of 4 or 5* with reduced uptake compared with baseline and residual mass(es) of any size. Residual uptake in BM higher than normal but less than baseline. | 1. ≥50% decrease in SPD from baseline of any measurable extranodal site 2. Spleen >50% regression in length beyond normal (≤13 cm) 3. No new lesions 4. No increase in nonmeasured lesions |
| SD | No metabolic response. Score of 4 or 5* with no significant change in FDG uptake from baseline. BM no change from BL. | Fails to attain criteria for CR, PR, or PD. No clear progression or improvement. |
| PD | 1. Progressive metabolic disease 2. New FDG-avid foci consistent with lymphoma | 1. New extranodal site >1 cm any axis or if <1 cm, must be attributable to lymphoma 2. An increase in LDi or SDi from nadir of 0.5 cm for lesions ≤2 cm or 1 cm for lesions >2 cm 3. Regrowth of previously resolved lesions 4. In the setting of splenomegaly at BL, an increase in splenic length by >50% from BL or if no splenomegaly at BL, new increase length >2 cm from BL 5. New or clear progression of preexisting nonmeasured lesions |
| Response . | Lugano PET-CT–based response . | Lugano CT-based response . |
|---|---|---|
| CR | Complete metabolic response. Score of 1, 2, or 3* with or without a residual mass on 5PS. No evidence of FDG-avid disease. | No extralymphatic sites of disease. Any abnormal size of organ at screening/baseline has returned to normal size. BM normal by morphology. |
| PR | Partial metabolic response. Score of 4 or 5* with reduced uptake compared with baseline and residual mass(es) of any size. Residual uptake in BM higher than normal but less than baseline. | 1. ≥50% decrease in SPD from baseline of any measurable extranodal site 2. Spleen >50% regression in length beyond normal (≤13 cm) 3. No new lesions 4. No increase in nonmeasured lesions |
| SD | No metabolic response. Score of 4 or 5* with no significant change in FDG uptake from baseline. BM no change from BL. | Fails to attain criteria for CR, PR, or PD. No clear progression or improvement. |
| PD | 1. Progressive metabolic disease 2. New FDG-avid foci consistent with lymphoma | 1. New extranodal site >1 cm any axis or if <1 cm, must be attributable to lymphoma 2. An increase in LDi or SDi from nadir of 0.5 cm for lesions ≤2 cm or 1 cm for lesions >2 cm 3. Regrowth of previously resolved lesions 4. In the setting of splenomegaly at BL, an increase in splenic length by >50% from BL or if no splenomegaly at BL, new increase length >2 cm from BL 5. New or clear progression of preexisting nonmeasured lesions |
Based on Cheson et al.11
FDG, fluorodeoxyglucose; LDi, longest diameter; LN, lymph node; 5PS, 5-point scale; PD, progressive disease; SDi, short axis (longest perpendicular diameter to the LDi); SPD, sum of the products of the perpendicular diameters for multiple lesions
5PS: 1 = no FDG uptake > background; 2 = FDG uptake ≤ mediastinum; 3 = FDG uptake > mediastinum but ≤ liver; 4 = FDG uptake moderately > liver; 5 = FDG uptake markedly > liver and/or new lesions.